Citalopram
Class
Furancarbonitrile SSRI
Indications
Post-stroke pathological crying
Migraines
Administration/Absorption
Oral
Single daily dose
Bioavailability is 80% following oral administration
Dosage
Distribution
Volume of distribution 12 L/kg
Mechanism
The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin
Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors
Has only very weak effects on norepinephrine and dopamine neuronal reuptake
Has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors
Antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs
Citalopram does not inhibit monoamine oxidase.
Excretion
Half-life 35 hrs
The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance
Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative
Side effects
The chronic administration of Citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder
Common side effects:
drowsiness, insomnia, nausea, weight changes, frequent urination, decreased sex drive, anorgasmia, dry mouth, increased sweating, trembling, diarrhea, excessive yawning, and fatigue
Less common side effects:
bruxism, vomiting, cardiac arrhythmia, blood pressure changes, dilated pupils, anxiety, mood swings, headache, and dizziness
Rare side effects:
convulsions, hallucinations, and severe allergic reactions
Interactions
Contraindications